25th EADV Congress day 3 highlight: Long-term safety of systemic psoriasis treatments

25th EADV Congress day 3 highlight: Long-term safety of systemic psoriasis treatments


At the EADV this year there’s been a tremendous
push to understand safety in long-term data sets that compile data from all the different
clinical trials for the various medications. In particular, at this meeting there have
been discussions with ixekizumab and apremilast, looking at global databases that include all
the clinical trials for these medications. What’s most remarkable about this data,
is that the data is actually so clean; there don’t seem to be signals that develop over
time for safety (of concern) as we get into longer periods of time with patients being
treated with these medications. For example, with ixekizumab we now have thousands
of patient-years, up over 7000 patient-years, and no new safety signals seem to be developing. What’s more, with more patients out to 4
years with apremilast, the generally considered quite good safety data seems to be
persisting over time. Multiple other drugs have shown long-term
safety and it’s very reassuring from the data that’s been presented at this meeting
that no new safety signals for systemic therapies for psoriasis seem to be developing.

Leave a Reply

Your email address will not be published. Required fields are marked *